Thank you for your many years of tireless dedication and commitment. Your quest for perfection and honesty is reflected in the financial condition and reporting of Simulations Plus... an example that is rare to find in public companies. The Simulation Plus shareholders give you a very big thank you and hope that your retirement is enjoyable.
What looked like a sales and earnings shortfall has already been booked in Q1. A large order slipped from Q4 into Q1 so we should see continued sales and earnings improvement in the coming reports. There are several new and positive items discussed in the conference call... There have been several cases where SLP software results have been accepted by regulatory agencies and as a result physical drug trials were waived and not required. The drug discovery industry is embracing software solutions and SLP is providing what they need. This is an exciting time to be invested in this industry and SLP has a leadership position. I encourage everyone to listen to the conference call replay that should be available on the SLP web site later today or tomorrow. Also, Seeking Alpha has a conference call transcript.
and closing at the high as well as a new 52 week high. We had a similar day on high volume about 3 weeks ago. It looks like someone wants a lot of shares. The next dividend announcement may surprise a lot of people... Last year at year end a big part of the dividend was paid early so now the current payout looks small. All the financial data that is presented makes it look like the dividend is .03 per quarter when in fact we may actually see 2 X that amount. In reality if SLP continues to pay as they have in the past this is a solid 5% return. In addition I am expecting continued growth in sales and earnings that will keep the share price on an up trend. I am still holding all my shares.
Simulations Plus, Inc. (SLP), a leading provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that it has completed the molecule design phase of its second NCE (new chemical entity) project, and is issuing requests for quotes to synthesize the new compounds for testing. This second NCE project follows the Company’s successful project that was completed last year to design new molecules to inhibit the malaria parasite.
Dr. Robert Clark, director of life sciences for Simulations Plus, said: “Our target for this second NCE project is cyclooxygenase-2 (COX-2).
A full detailed report is available at Taglich... Sorry but I can't post the information... Yahoo has made it impossible to post information from other sites...
Software Programs Will Help Prioritize Testing for the National Toxicology Program
Simulations Plus, Inc. (SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, announced today that it has signed a Material Transfer Agreement (MTA) with the Division of the National Toxicology Program (DNTP) of the U.S. National Institute of Environmental Health Sciences (NIEHS) to provide licenses for its GastroPlus™, ADMET Predictor™, and MedChem Studio™ software programs for use by the DNTP/NIEHS. The DNTP within the NIEHS is conducting research along with several agencies, including the U.S. Environmental Protection Agency, the U.S. Army, the National Human Genome Institute, and the Centers for Disease Control in the National Toxicology Project.
SLP has a very busy month ahead.. The professional meetings and conferences have always been a good source for new customers. Because the SLP engineers that actually design and write the code for the offerings are presenting at these conferences, scientists that attend these meetings have an opportunity to discuss specific product details that would be difficult for a sales person to address. These one on one discussions are very important to the chemist that is looking for solutions to specific problems... The SLP designer can provide specific feed back regarding product capability and will in many cases gain valuable information on how to improve the SLP offerings.
The busy June schedule should result in continued sales and earnings growth for SLP.
This is a big deal and very important. Think about it...Eliminating drug trials because software provided the results. The implications are huge. And the FDA is also a user of SLP software. If you are in the drug discovery business it's obvious that you need these tools. Not only to reduce time and cost in your business but also to assure yourself that you have a clear understanding of what the FDA is looking at when they review your submission. This is the way of the future for drug discovery. The brute force methods of trial and error are way too expensive to continue. Business solutions using software are exploding all around us and the tools that SLP provides are key to streamlining the drug discovery business.
There is more in the press release...
"Each of these involved a consulting contract with Simulations Plus to assist the sponsor with the GastroPlus simulations and model development. Simulations Plus also provided assistance in preparation of the submittals to the regulatory agencies." The assistance in preparation of the submittals part can be a huge new area of revenue for SLP.
And the part in the PR about submitting files... All this saves time and money.
"Regulatory agencies in the U.S., Europe, China, and Japan all have GastroPlus for their internal use, so sponsors can submit GastroPlus input files to these agencies to make evaluation of results fast and convenient."
This PR is a good example of what to look for to make a determination if SLP will be a bigger company next year. I continue to hold all my shares.
Simulations Plus Software Used in Regulatory Submittals
Simulations Plus, Inc. (SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, today announced that results of simulations using its GastroPlus™ software have been submitted to major regulatory agencies as part of applications by its customers.
John DiBella, vice president of marketing and sales for Simulations Plus, noted, “The first submittal to a regulatory agency was reported by Pfizer in 2008, which resulted in Pfizer being allowed to forego a human trial after GastroPlus simulations showed that it would not be necessary. In the past 12 months, four additional customers have submitted simulation results to the U.S. Food and Drug Administration (FDA), the European Medical Agency (EMA), and the British Medical Health Regulatory Agency (MHRA). Each of these involved a consulting contract with Simulations Plus to assist the sponsor with the GastroPlus simulations and model development. Simulations Plus also provided assistance in preparation of the submittals to the regulatory agencies. The acceptance of simulation results by these agencies is an indication of the growing importance of simulation and modeling technology in pharmaceutical research and development.”
Walt Woltosz, chairman and chief executive officer of Simulations Plus, added: “The four submittals John describes resulted in:
1. Eliminating a clinical trial to demonstrate that fasted and fed states would not produce significantly different results for the absorption of the drug candidate.
2. Identifying the particle size specification for a re-engineered product to ensure bioequivalence to an existing product.
3. Explaining the variations observed in different formulations.
4. Scaling complex processes involving metabolism and carrier-mediated transport from adult to pediatric/neonate populations.
These four submissions signal a developing trend for the use of simulation and modeling r
Including a publication by the FDA ! Check it out on the SLP web site. So if you are working on drug discovery and you know that the FDA is using SLP software which software are you going to use?
Here we go again... Please show us the information or tell us where we can find the data that substantiates your claim that Walt and his wife are selling shares. It's been so long that they have sold any I can't even find it anymore. If and when they do sell shares you will be able to determine this rather promptly ( In less than 3 days ) by looking at the SEC web site because they are required to file a form 4. The last time Walt filed a form 4 he converted options to shares and he did not sell any shares... When a CEO does not sell upon conversion it usually means that he believes the business is in great shape and he expects the shares to be worth more later. So humor us... Where is the data that he sold shares?
I have taken a much longer term view on SLP and have been richly rewarded. I have been a shareholder since the early 2000's. The stock price had a low of 26 cents at that time... That's a 15 X gain... So a 11% price decrease in the most recent 12 months doesn't mean much. Admittedly the 2007-2008 decline was a significant event but at that time the stock was selling for over 50 X earnings. So now the question is what are investors willing to pay for SLP. I doubt that 50 X earnings is in the cards again, unless there are major advancements with the Drug Design Project. But looking at the earnings estimate for 2014 we are currently trading under 16 times earnings. Another question is what yield dividend investors will be happy with. The current 6%+ is inviting for anyone looking for a dividend return. Given the growth and the quality of the balance sheet I think the current dividend is an added incentive for investors to own SLP stock.
So your question was "Tell me who is going to buy the stock when its price per share is down 11.24% in the last 52 weeks"... I have no way of knowing who that might be but I do believe that SLP should be bought at current levels. If it was good a year ago it should be even better now. The high volume in the last 2 days gives the appearance that a large holder sold some shares... The other side of that is that someone also bought those shares expecting a higher stock price... I'm confident that the buyer is also looking at the current growth, the pristine balance sheet and the very attractive yield. If the apparent seller has more stock to sell and becomes impatient and more aggressive you might find a very attractive price for SLP stock in the near term.
adam... You are still making the INCORRECT ASSUMPTION that the gifted shares were given to Walt's wife. The answer is NO THEY WERE NOT. The shares were gifted by Mrs. Woltosz to someone else. Check the SEC filings... The count for the number of shares held by Walt AND his wife WENT DOWN after the transaction. You should get your info from the SEC web site... Secondary news and information providers are notoriously bad and inaccurate. In this specific case Etrade is correct... Mrs. Waltosz did in fact gift those shares... but the shares went to someone else... They were not gifted to her. When a person "gifts" something they are giving something to another person... They are not receiving.
No... That is not correct... Walt did not gift them to his wife. Where do you get this stuff???? Look at the SEC flings and you can see the reduction in holdings AFTER the gift. Walt and his wife are for practicable purposes one and the same person when it comes to SEC stock filings. If you really believe that Walt gifted the shares to his wife then please show us the evidence. BTW... Even if he did gift them to his wife... so what ????
adam... This stock gift has been discussed MANY times on this message board. Walt's wife gifted those shares to another person. The shares were not gifted to her by the company as you have implied. As far as the officers buying shares goes... The officers are granted stock options as an incentive to improve the business. The most recent options converted to stock by Walt were not sold... Walt is holding onto those shares. I think he is holding the shares because he thinks they will be worth more at a later date.